Clinical Trials

Carcinoma, Intraductal, Noninfiltrating

NCT06930859 2026-05-22

ELEGANCE

Recruiting

2,766 enrolled

Breast Neoplasms

NCT07174336 2026-05-22

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

920 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07349069 2026-05-22

A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer

5,500 enrolled

Breast Neoplasms

NCT07492641 2026-05-22

KANDELA-302

1,056 enrolled

HR+/HER2- Breast Cancer

NCT03425838 2026-05-20

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

1,050 enrolled

Breast Neoplasm Female

NCT04546009 2026-05-19

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

992 enrolled

Breast Neoplasms

NCT06760637 2026-05-19

FourLight-3

1,035 enrolled

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT07029399 2026-05-19

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Phase 1 Recruiting

361 enrolled

Phase 1/2 Not yet recruiting

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07596212 2026-05-19

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

100 enrolled

BreastOther

Breast Neoplasms, Sexual Dysfunctions, Psychological

NCT06757634 2026-05-18

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

1,180 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05512364 2026-05-15

TREAT ctDNA

220 enrolled

Breast Neoplasms

NCT06380751 2026-05-15

EvoPAR-BR01

500 enrolled

Advanced Breast Cancer

NCT07085767 2026-05-15

OPERA-02

1,000 enrolled

Breast Neoplasms

NCT02297438 2026-05-14

A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

Phase 3 Completed

340 enrolled 33 charts

Breast Neoplasms, Neoplasm Metastasis

NCT05085002 2026-05-14

A Study of Lerociclib in Participants With Advanced Breast Cancer

Phase 2 Terminated

100 enrolled 14 charts

Advanced Breast Cancer

NCT05827081 2026-05-14

Adjuvant WIDER

1,400 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms, Breast Neoplasms, Male

NCT07391774 2026-05-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

1,978 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT07178743 2026-05-12

Emulation of the PALOMA-2 Trial

Completed

6,097 enrolled

Advanced Breast Cancer

NCT07225790 2026-05-12

Emulation of the MONARCH-3 Trial Using Specialty Oncology Electronic Health Records Databases

Completed

3,883 enrolled

Advanced Breast Cancer

NCT05774951 2026-05-08

CAMBRIA-1

4,300 enrolled

Breast Neoplasms

NCT06507618 2026-05-08

POWER II

354 enrolled

Breast Neoplasms

NCT06671912 2026-05-08

LoTam

Phase 3 Suspended

1,156 enrolled

Breast Carcinoma In Situ

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT02918084 2026-05-06

GIM10-CONSENT

1,000 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT04553133 2026-05-06

PF-07104091 as a Single Agent and in Combination Therapy

157 enrolled

BreastGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT07570966 2026-05-06

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Phase 1/2 Not yet recruiting

217 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Phase 2 Active not recruiting

17 enrolled 10 charts

Advanced Breast Carcinoma

NCT06905301 2026-05-05

IMPULSE

Recruiting

240 enrolled

Breast Neoplasms

NCT06790693 2026-05-04

INAVO123

450 enrolled

Breast Neoplasms

NCT06998407 2026-05-04

AVZO-023-1001

Phase 1/2 Recruiting

380 enrolled

Phase EARLY_PHASE1 Completed

HR+/HER2- Breast Cancer

NCT03962647 2026-04-30

A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer

31 enrolled

Estrogen Receptor-positive Breast Cancer

NCT03633331 2026-04-29

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Phase 2 Completed

93 enrolled 16 charts

Estrogen Receptor-positive Breast Cancer

NCT04852887 2026-04-23

DEBRA

1,670 enrolled

Breast Neoplasms

NCT04964934 2026-04-21

SERENA-6

315 enrolled

Phase 1 Active not recruiting

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT05307705 2026-04-20

PIKASSO-01

193 enrolled

Breast Neoplasms

NCT05780567 2026-04-17

Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer

1,946 enrolled

Breast Neoplasms

NCT06179303 2026-04-16

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Phase 2 Recruiting

60 enrolled

Anatomic Stage III Breast Cancer AJCC v8

NCT02095184 2026-04-15

GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients

Phase NA Terminated

42 enrolled 13 charts

Breast Neoplasms

NCT01127295 2026-04-14

PHACS

Phase 4 Completed

2,000 enrolled